1. Scrip
  2. >>Business

Stada consolidates and restructures Russian subsidiaries

 
• By Maria Bailey

Assets of [C#200400003:Stada]'s two subsidiaries in Russia, NizhpharmandMakiz-Pharma, have been consolidated and re-named [C#200400003:Stada] CIS, but the two companies' products will continue to be marketed under their previous brand names.

Assets of Stada's two subsidiaries in Russia, NizhpharmandMakiz-Pharma, have been consolidated and re-named Stada CIS, but the two companies' products will continue to be marketed under their previous brand names.

Dmitriy Yefimov, Stada's vice-president for Russia and the CIS and Nizhpharm's director general, will become the head of Stada CIS's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.